Editor's note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. So, I think it has a huge impact. It has ...
Immune checkpoint inhibitors (ICIs) are remarkably effective in some patients with cancer, whereas other patients do not respond or develop resistance over time. Strategies for reinvigorating ...
While the treatment landscape has really exploded since the early days, there aren't any non-JAK inhibitors approved yet. Here, Prithviraj Bose, MD, professor in the Department of Leukemia at the ...
VIENNA — The highly selective oral Janus kinase (JAK) inhibitor SHR0302 (ivarmacitinib) enables more patients with active rheumatoid arthritis to meet American College of Rheumatology (ACR) response ...
Researchers at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai have demonstrated the potential for a new combination therapy to improve outcomes for patients with ...
Eli Lilly and Incyte’s oral JAK inhibitor has shown benefit in hair regrowth in paediatric patients with severe alopecia areata. In the Phase III BRAVE-AA-PEDS trial (NCT05723198) 54.1% and 31% of ...
A first-in-class topical pan-Janus kinase (JAK) inhibitor significantly improved symptoms of moderate to severe chronic hand eczema in two randomized phase III trials. At week 16, more patients ...
DelveInsight’s, “Janus Kinase (JAK) Inhibitor Pipeline Insight, 2025” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Janus Kinase (JAK) Inhibitor pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback